Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BGB-C354 + tislelizumab
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BGB-C354 + tislelizumab is an investigational **combination therapy** under clinical development for advanced solid tumors. BGB-C354 is an antibody-drug conjugate (ADC) targeting B7-H3 (CD276), a tumor-associated antigen highly expressed in various solid tumors, designed to deliver cytotoxic payloads directly to B7-H3 expressing cancer cells, causing DNA damage and apoptosis. Tislelizumab is a monoclonal antibody that targets PD-1 (programmed death-1) receptor, acting as a checkpoint inhibitor to enhance T-cell-mediated immune responses against tumor cells. The combination aims to leverage BGB-C354’s targeted cytotoxicity together with the immune checkpoint blockade of tislelizumab for potential synergistic antitumor activity. The combination is being studied in a first-in-human Phase 1a/1b clinical trial evaluating safety, tolerability, pharmacokinetics, and preliminary antitumor activity in adults with advanced, metastatic, or unresectable solid tumors whose cancers are not amenable to curative therapy[1][3][5][7][9].
- Other names
- BGB-C354 + tislelizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)B7-H3TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on BGB-C354 + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BGB-C354 + tislelizumab.